Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 ETF Trust (NYSE: SPY) total return over the last 12 months is 29.5%. But there is no question some big-name stocks performed better than others along the way.
Catalyst’s Bumpy Ride: One company that has been a great investment in the last year has been the biopharmaceutical company Catalyst Pharmaceuticals Inc (NASDAQ: CPRX).
Catalyst Pharmaceuticals develops treatments for rare diseases, such as autoimmune disorder Lambert-Eaton Myasthenic Syndrome (LEMS). The big news for Catalyst in recent years came in 2018 when the company’s Firdapse became the first LEMS treatment ever approved in the U.S. Firdapse was subsequently approved in Japan in 2019.
In early 2020, Catalyst aggressively expanded its sales team to help monetize Firdapse and the company is actively undergoing trials to potentially expand Firdapse’s label to muscle-specific kinase myasthenia gravis (MuSK-MG) and other indications.
Meanwhile, the company is also facing …